Viruses have evolved the ability to bind and enter cells through interactions with a wide
variety of cell macromolecules. We engineered peptide-modified adeno-associated virus …

Introduction The blood–brain barrier (BBB) restricts brain access of virtually all
macromolecules. Receptor-mediated transcytosis (RMT) is one strategy toward their brain …

The brain microenvironment is tightly regulated, and the blood–brain barrier (BBB) plays a
pivotal role in maintaining the homeostasis of the central nervous system. It effectively …

Gene therapy using recombinant adeno-associated virus (rAAV) relies on safe, efficient, and
precise in vivo gene delivery that is largely dependent on the AAV capsid. The …

Alzheimer's disease (AD) is the most common age‐related neurodegenerative disorder
leading to cognitive decline. Excessive cytosolic calcium (Ca2+) accumulation plays a …

Developing vehicles that efficiently deliver genes throughout the human central nervous
system (CNS) will broaden the range of treatable genetic diseases. We engineered an …

Carbonic anhydrase IV (Car4) is a newly identified receptor that allows adeno-associated
virus (AAV) 9P31 to cross the blood-brain barrier and achieve efficient infection in the central …

Current adeno-associated virus (AAV) gene therapy using nature-derived AAVs is limited by
non-optimal tissue targeting. In the treatment of muscular diseases (MD), high doses are …

Today, adeno-associated virus (AAV)-based vectors are arguably the most promising in vivo
gene delivery vehicles for durable therapeutic gene expression. Advances in molecular …

Adeno-associated viruses (AAVs) are foundational gene delivery tools for basic science and
clinical therapeutics. However, lack of mechanistic insight, especially for engineered vectors …